QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.

Autor: Khera E; PK Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA., Dharmarajan L; PK Sciences, Translational Medicine, Novartis Biomedical Research, Basel, Switzerland., Hainzl D; PK Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA., Engelhardt V; PK Sciences, Translational Medicine, Novartis Biomedical Research, Basel, Switzerland., Vostiarova H; PK Sciences, Translational Medicine, Novartis Biomedical Research, Basel, Switzerland., Davis J; PK Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA., Ebel N; Oncology, Novartis Biomedical Research, Basel, Switzerland., Wuersch K; Preclinical Safety, Novartis Biomedical Research, Basel, Switzerland., Romanet V; Oncology, Novartis Biomedical Research, Basel, Switzerland., Sharaby S; PK Sciences, Translational Medicine, Novartis Biomedical Research, East Hanover, NJ, USA., Kearns JD; PK Sciences, Translational Medicine, Novartis Biomedical Research, Cambridge, MA, USA. jeff.kearns@novartis.com.

Publikováno v: Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2024 Dec 17; Vol. 52 (1), pp. 7. Date of Electronic Publication: 2024 Dec 17.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.